L Cataliotti

Summary

Affiliation: University of Florence
Country: Italy

Publications

  1. ncbi Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
    L Cataliotti
    University of Florence, Florence, Italy
    Eur J Cancer 43:660-75. 2007
  2. ncbi Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer
    L Livi
    Radiotherapy Unit, University of Florence, Italy
    J Chemother 21:558-65. 2009
  3. ncbi The management of elderly patients with T1-T2 breast cancer treated with or without radiotherapy
    L Livi
    Unita Di Radioterapia, University of Florence, Firenze, Italy
    Eur J Surg Oncol 31:473-8. 2005
  4. ncbi Adjuvant trastuzumab in breast cancer: experience from the University of Florence
    L Livi
    Radiotherapy Unit, University of Florence, Italy
    J Chemother 22:115-8. 2010
  5. ncbi Monitoring surgical treatment of screen-detected breast lesions in Italy
    V Distante
    Universita di Firenze, Dipartimento Area Critica Medico Chirurgica, Sezione Clinica Chirurgica, Italy
    Eur J Cancer 40:1006-12. 2004
  6. ncbi The impact of young age on breast cancer outcome
    L Livi
    Department of Radiation Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    Eur J Surg Oncol 36:639-45. 2010
  7. ncbi Lymphoscintigraphy and gamma probe tracing in detecting breast cancer lymph node involvement: can they replace axillary lymph node dissection?
    L Vaggelli
    UO Medicina Nucleare Careggi, Azienda Ospedaliera Careggi, Florence, Italy
    Tumori 86:322-4. 2000
  8. ncbi Intraductal breast carcinoma. Review of a multicenter series of 350 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy
    S Ciatto
    Centro per lo Studio e la Prevenzione Oncologica, University, Florence, Italy
    Tumori 76:552-4. 1990
  9. ncbi Quality indicators in breast cancer care
    M Rosselli del Turco
    EUSOMA, Florence, Italy
    Eur J Cancer 46:2344-56. 2010
  10. ncbi Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue
    C Orlando
    Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
    Endocr Relat Cancer 11:323-32. 2004

Collaborators

Detail Information

Publications19

  1. ncbi Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
    L Cataliotti
    University of Florence, Florence, Italy
    Eur J Cancer 43:660-75. 2007
    ..The aim of this paper is to contribute to the increase in the level of care in a breast unit, as the input of qualified health professionals increases the quality of breast cancer patient care...
  2. ncbi Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer
    L Livi
    Radiotherapy Unit, University of Florence, Italy
    J Chemother 21:558-65. 2009
    ..028, respectively. No significant difference between the two regimens was observed with regards to number of involved nodes. DC and CMF produced similar outcome in breast cancer patients...
  3. ncbi The management of elderly patients with T1-T2 breast cancer treated with or without radiotherapy
    L Livi
    Unita Di Radioterapia, University of Florence, Firenze, Italy
    Eur J Surg Oncol 31:473-8. 2005
    ..The aim of the current study is to identify a subgroup of patients with breast cancer who have a low risk of local recurrence after conservative surgery in order to avoid radiotherapy treatment...
  4. ncbi Adjuvant trastuzumab in breast cancer: experience from the University of Florence
    L Livi
    Radiotherapy Unit, University of Florence, Italy
    J Chemother 22:115-8. 2010
    ..The cumulative incidence of cardiotoxicity was 14.5%. In our experience trastuzumab given postoperatively with adjuvant chemotherapy was well tolerated and produced optimal clinical results in terms of disease-free survival...
  5. ncbi Monitoring surgical treatment of screen-detected breast lesions in Italy
    V Distante
    Universita di Firenze, Dipartimento Area Critica Medico Chirurgica, Sezione Clinica Chirurgica, Italy
    Eur J Cancer 40:1006-12. 2004
    ..A continuous monitoring should be performed and appropriate action taken in order to verify the effectiveness of the corrective actions and to provide screen-detected patients with the best quality of care...
  6. ncbi The impact of young age on breast cancer outcome
    L Livi
    Department of Radiation Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    Eur J Surg Oncol 36:639-45. 2010
    ..We conducted a retrospective analysis in order to evaluate the impact of age on women aged less than 35 years affected by breast cancer...
  7. ncbi Lymphoscintigraphy and gamma probe tracing in detecting breast cancer lymph node involvement: can they replace axillary lymph node dissection?
    L Vaggelli
    UO Medicina Nucleare Careggi, Azienda Ospedaliera Careggi, Florence, Italy
    Tumori 86:322-4. 2000
    ..Recently, radioisotope-guided sentinel node biopsy (SNB) has been proposed as a promising technique for staging breast cancer patients...
  8. ncbi Intraductal breast carcinoma. Review of a multicenter series of 350 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy
    S Ciatto
    Centro per lo Studio e la Prevenzione Oncologica, University, Florence, Italy
    Tumori 76:552-4. 1990
    ..Four patients died of contralateral breast cancer, free of ipsilateral recurrence. A careful follow-up of the contralateral breast in DCIS cases looks as important as surveillance of the conserved breast...
  9. ncbi Quality indicators in breast cancer care
    M Rosselli del Turco
    EUSOMA, Florence, Italy
    Eur J Cancer 46:2344-56. 2010
    ..Breast Units in Europe are invited to comply with these indicators and monitor them during their periodic audit meetings...
  10. ncbi Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue
    C Orlando
    Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
    Endocr Relat Cancer 11:323-32. 2004
    ..Featuring a possible role of somatostatin analogs in combined endocrine therapies for breast cancer, our results seem to confirm that the sst2 status of the tumor should be previously investigated...
  11. ncbi Lack of prognostic value of p53 protein expression in node-negative breast cancer
    S Bianchi
    Institute of Anatomical Pathology and Histology, University of Florence, Italy
    Tumori 83:669-72. 1997
    ..CONCLUSIONS: We did not find any evidence supporting the use of p53 immunostaining in current practice as an independent prognostic indicator or as a discriminant factor for adjuvant treatment of node-negative breast cancer patients...
  12. ncbi Prognostic significance of c-erbB-2 expression in node negative breast cancer
    S Bianchi
    University Institute of Anatomia e Istologia Patologica, Florence, Italy
    Br J Cancer 67:625-9. 1993
    ..C-erbB-2 expression is of no value to predict the clinical course of node negative patients in the current practice...
  13. ncbi [Somatostatin receptors in non-endocrine tumours]
    C Casini Raggi
    , , Florence, Italy
    Minerva Endocrinol 26:149-58. 2001
    ..In breast cancer, it is possible that sensitivity to estrogens may have a positive influence on the expression of sst2. This might justify clinical trials with ss in breast cancer...
  14. ncbi Dermo quiz: the illness and death of Anna Maria Lodovica de' Medici, Palatine Electress (1667-1743)
    L Cataliotti
    Dipartimento di Area Critica Medico Chirurgica, University of Florence, Florence, Italy
    Dermatol Ther 23:S37-40. 2010
    ..The opportunity to exhume her corpse in the frame of the Medici Project will supply evidence for this interpretation...
  15. ncbi Risk of infiltrating breast cancer subsequent to lobular carcinoma in situ. The Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer)
    S Ciatto
    Centro per lo Studio e la Prevenzione Oncologica, , Italy
    Tumori 78:244-6. 1992
    ..The study confirms the higher risk of ipsilateral and contralateral cancer in LCIS patients and warns about the possible hazards of limited surgery in these cases...
  16. ncbi EUSOMA accreditation of breast units
    R W Blamey
    EUSOMA Secretariat Via del Pratellino, 7, 50131 Florence, Italy
    Eur J Cancer 42:1331-7. 2006
    ..EUSOMA Guidelines have been published on several aspects of breast cancer and are on service provision as well as giving clinical guidance and providing the basis for audit...
  17. ncbi Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy
    U Veronesi
    Division of Senology, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Ann Oncol 16:383-8. 2005
    ..The aim of the study was to assess the role of axillary radiotherapy (RT) in reducing axillary metastases in patients with early breast cancer who did not receive axillary dissection...
  18. ncbi Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS
    N Bijker
    Department of Radiation Oncology, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 87:615-20. 2002
    ..Selection of patients may explain the differences in outcome of the randomised patients, and those not-entered. Thus, the results of this trial may not be applicable to all patients with ductal carcinoma in situ...
  19. ncbi The Hamburg statement: the partnership driving the European agenda on breast cancer
    J Jassem
    Division of Breast Surgery, Fondazione Salvatore Maugeri, Via Ferrata 8, I-27100 Pavia, Italy
    Eur J Cancer 40:1810-1. 2004